INTRODUCTION {#s1}
============

Urothelial carcinoma (UC) is a significant health problem. In 2008, it led to an estimated 150,200 deaths worldwide \[[@R1]\]. Twenty-five percent of UCs were invasive \[[@R2], [@R3]\]. According to the European Urology Association (EAU), radical cystectomy (RC) with bilateral pelvic lymphadenectomy was the gold standard treatment for patients with muscle-invasive tumors \[[@R4]\].

The classic MVAC regimen (methotrexate, vinblastine, doxorubicin and cisplatin) \[[@R5]\] was established as the most effective regimen (4-week-per-cycle) in the neoadjuvant chemotherapy setting \[[@R6]\], and the first recognized option for patients with locally advanced or metastatic UC \[[@R7]\]. In 1993, the classic MVAC regimen was modified into dose-dense MVAC (dd-MVAC) which was administered in cycles of 14 days. Dd-MVAC was shown to have fewer dose delays and a more favorable toxicity profile than classic MVAC group \[[@R8]\] in a randomized phase III trial, however in another study \[[@R9]\], similar pathological responses were observed between the two groups.

To systematically review the safety and efficacy of dose-dense chemotherapy, we assessed the pathologic complete response (pCR), objective response rate (ORR), overall survival (OS) and adverse events (AEs) of dose-dense chemotherapy, dd-MVAC in particular, in patients with UC. We also compared the efficacy and safety of dd-MVAC with classic MVAC.

RESULTS {#s2}
=======

Literature search {#s2_1}
-----------------

The initial search yielded 849 unique articles after deletion of duplicates. After title and abstract screening, 555 were excluded as they were case reports, letters, review articles, or irrelevant to urothelial cancer, leaving 294 articles for full review. After assessing the full texts of these potentially relevant studies, 284 were excluded for the following reasons: 189 were researches on radiation therapy, 85 were completely not associated with dose-dense chemotherapy, 5 were about adjuvant therapy, 4 contained no relative outcomes, and 1 was with a too small sample size. Ultimately, 10 eligible articles \[[@R7], [@R9]--[@R17]\] involving a total of 1093 patients were included for analyses. No additional unpublished trials were added to the literature search results. A flow diagram of the trial selection process is shown in Figure [1](#F1){ref-type="fig"}.

![A flow diagram of the trial selection process](oncotarget-08-71117-g001){#F1}

Study characteristics {#s2_2}
---------------------

Results of the literature search identified 10 eligible papers. Among those papers, three \[[@R7], [@R9], [@R16]\] were controlled trials comparing dd-MVAC with classic MVAC, one \[[@R17]\] was another controlled trial comparing a dd-GC (gemcitabine 2500 mg/m2 and cisplatin 70 mg/m2, q 2 weeks) regimen with dd-MVAC which suggested that although not superior to dd-MVAC, dd-GC was better tolerated, and one \[[@R11]\] was AG-TC which was doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin. The rest were single-arm trials exploring the safety and/or the activity of dd-MVAC regimen. Dd-MVAC chemotherapy consisted of methotrexate (MTX) 30 mg/m2, vinblastine (VBL) 3mg/m2, adriamycin (ADM) 30 mg/m2 and cisplatin (CDDP) 70 mg/m2, administered in cycles of 14 days. Classic MVAC was a 4-week-per-cycle regimen which was also the combination of MTX 30 mg/m2, VBL 3 mg/m2, ADM 30 mg/m2 and CDDP 70 mg/m2. The majority of the patients were men. The age ranged from 32 to 83 years. The basic characteristics of the included studies are detailed in Table [1](#T1){ref-type="table"}.

###### Basic characteristics of the included studies

  Author            Year   Country       Tumor type                                 Type of study            No. of patients   Sex (Male/Female)   Median age (range) (y)   Tumor stage                              Chemotherapy regimens (mg/m2)               No. of planned cycles   No. of pCR (total)
  ----------------- ------ ------------- ------------------------------------------ ------------------------ ----------------- ------------------- ------------------------ ---------------------------------------- ------------------------------------------- ----------------------- --------------------
  van de Putte EE   2016   Netherlands   Muscle invasive bladder cancer (MIBC)      Retrospective            dd-MVAC: 80       60/20               mean (SD) 57 (8)         T1-4 N0-3 M0-1                           dd-MVAC (M 30, V 3, D 30, C 70 q 2 weeks)   4                       23 (80)
                                                                                                             MVAC: 35          26/9                59 (9)                   MVAC (M 30, V 3, D 30, C 70 q 4 weeks)   4                                           7 (35)                  
                                                                                                             GC: 51            36/15               63 (8)                   GC (G 1000, C 70 q 3 weeks)              4                                           16 (51)                 
  Bamias A          2013   Greek         Advanced urothelial cancer (UC)            Prospective, Phase III   dd-MVAC: 66       53/10               66 (35-76)               cT4b N2 N3                               dd-MVAC (M 30, V 3, A 30, C 70 q 2 weeks)   ≥ 6                     5 (45)
                                                                                                             dd-GC: 64         55/8                65 (34-80)               dd-GC (G 2500, C 70 q 2 weeks)           ≥ 6                                         5 (49)                  
  Pouessel D        2016   France        Advanced urothelial bladder cancer         Retrospective            dd-MVAC: 189      160/29              63 (57-67)               T2-4a N1-3 M0                            dd-MVAC (M 30, V 3, D 30, C 70 q 2 weeks)   4-6                     58 (166)
                                                                                                             MVAC: 52          43/9                58 (55-66)               MVAC (M 30, V 3, D 30, C 70 q 4 weeks)   3-4                                         17 (45)                 
  Sternberg CN      2005   Multicenter   Advanced urothelial cancer (UC)            phase III                dd-MVAC: 134      105/29              61 (36--76)              NA                                       dd-MVAC (M 30, V 3, D 30, C 70 q 2 weeks)   6                       28 (134)
                                                                                                             MVAC: 129         107/22              62 (32--81)              MVAC (M 30, V 3, D 30, C 70 q 4 weeks)   4                                           12 (129)                
  Choueiri TK       2014   Multicenter   Muscle invasive urothelial cancer (MIUC)   Prospective, phase II    39                28/11               NA                       cT2-cT4 N0-1 M0                          dd-MVAC (M 30, V 3, D 30, C 70 q 2 weeks)   4                       10 (36)
  Galsky MD         2007   USA           Advanced Urothelial Carcinoma              Phase II                 25                NA                  67 (43--79)              NA                                       AG-TC\*                                     5                       5 (25)
  Plimack ER        2014   Multicenter   Muscle invasive bladder cancer (MIBC)      Prospective, phase II    44                30/14               64 (44-83)               cT2-T4a N0-N1 M0                         dd-MVAC (M 30, V 3, D 30, C 70)             3                       15 (40)
  Blick C           2012   UK            Muscle invasive bladder cancer (MIBC)      Retrospective            80                64/16               60 (41-74)               T2-4a N0-2 M0                            dd-MVAC (M 30, V 3, D 30, C 70 q 2 weeks)   3 or 4                  26 (60)
  McConkey DJ       2015   USA           Muscle invasive urothelial cancer (MIUC)   Phase II                 60                40/20               64 (42--79.6)            T1-4a N0 M0                              dd-MVAC (M 30, V 3, D 30, C 70 q 2 weeks)   4                       23 (60)
  Edeline J         2012   France        Advanced bladder cancer                    Retrospective            45                36/9                58 (36--79)              NA                                       dd-MVAC (M 30, V 3, D 30, C 70 q 2 weeks)   ≥ 1                     4 (38)

NA: not available.

AG--TC\*: doxorubicin 50 mg/m2 plus gemcitabine 2000 mg/m2 every other week \*5 cycles followed by paclitaxel 65 mg/m2 i.v. plus carboplatin 1.7 i.v. weekly \*12 cycles.

Response and survival {#s2_3}
---------------------

In the ten studies with a full cohort of 684 patients who received dd-MVAC, the pooled pCR was 27.8% (95% confidence interval (CI) 0.217--0.349, *p \<* 0.001) (Figure [2](#F2){ref-type="fig"}). The rate of pCR was presented in three controlled studies that compared dd-MVAC with classic MVAC. No significant difference was detected in the odds of achieving a pCR with dd-MVAC versus classic MVAC (odds ratio 1.52, 95% CI 0.78--2.98, *P =* 0.22, *I*^2^ = 55%, random-effects model) (Figure [3A](#F3){ref-type="fig"}). In addition, there was no significant improvement in terms of ORR between the dd-MVAC group compared with classic MVAC group, with an odds ratio of 0.98 (95% CI 0.48--1.99, *p =* 0.96, I^2^ = 60%, random-effects model) (Figure [3B](#F3){ref-type="fig"}).

![The pooled pathologic complete response (pCR) in the ten included studies](oncotarget-08-71117-g002){#F2}

![(**A**) The odds ratios of pathologic complete response (pCR) in the controlled trials comparing dd-MVAC and classic MVAC; (**B**) The odds ratios of objective response rate (ORR) in the controlled trials comparing dd-MVAC and classic MVAC; (**C**) Forest plots of the pooled hazard ratios (HRs) for OS.](oncotarget-08-71117-g003){#F3}

As for long-term survival, a significantly improved OS was noted with dd-MVAC treatment when compared with classic MVAC treatment (hazard ratios (HR) 0.77, 95% CI 0.61--0.97, *p =* 0.03, *I*^2^ = 0%, fixed-effects model) (Figure [3C](#F3){ref-type="fig"}).

Toxicity {#s2_4}
--------

We analyzed the rates of all-grade and grade 3 or more AEs in the ten included studies to evaluate the safety of dose-dense chemotherapy. In all-grade AEs, the highest risk was found for fatigue (60.7%, 95% CI 0.505--0.701, *I*^2^ = 49.967%, fixed-effects model). Thrombocytopenia was also common with the event rate of 43.2% (95% CI 0.308--0.566, *I*^2^ = 67.955%) using a random-effects model (Table [2](#T2){ref-type="table"}, Figure [4](#F4){ref-type="fig"}).

###### The rate of all-grade and grade ≥ 3 adverse events (AEs) for dose-dense MVAC

  -----------------------------------------------------------------------------
  All-grade adverse events   Model           Event rate with 95% CI   I^2^
  -------------------------- --------------- ------------------------ ---------
  Fatigue                    Fixed model     0.607 (0.505--0.701)     49.967

  Febrile neutropenia\       Fixed model\    0.084 (0.058--0.120)\    0.000\
  Neuropathy                 Fixed model     0.055 (0.032--0.095)     0.000

  Kidney injury\             Random model\   0.091 (0.033--0.229)\    84.160\
  Thrombocytopenia           Random model    0.432 (0.308--0.566)     67.955
  -----------------------------------------------------------------------------

  -------------------------------------------------------------------------------------
  Grade ≥ 3 adverse events           Model           Event rate with 95% CI   I^2^
  ---------------------------------- --------------- ------------------------ ---------
  Dehydration\                       Fixed model\    0.051 (0.019--0.128)\    0.000\
  Fatigue\                           Fixed model\    0.077 (0.049--0.118)\    4.430\
  Hyponatremia\                      Fixed model\    0.019 (0.005--0.074)\    0.000\
  Kidney injury\                     Fixed model\    0.025 (0.012--0.052)\    9.112\
  Mucositis\                         Fixed model\    0.029 (0.009--0.087)\    0.000\
  Nausea/vomiting\                   Fixed model\    0.046 (0.022--0.094)\    0.000\
  Neuropathy\                        Fixed model\    0.011 (0.002--0.052)\    0.000\
  Sepsis                             Fixed model     0.074 (0.038--0.142)     42.331

  Stomatitis\                        Fixed model\    0.038 (0.012--0.112)\    11.398\
  Thrombosis\                        Fixed model\    0.038 (0.016--0.088)\    0.000\
  Anemia\                            Random model\   0.094 (0.035--0.228)\    87.575\
  Neutropenia/febrile neutropenia\   Random model\   0.175 (0.096--0.296)\    84.806\
  Thrombocytopenia                   Random model    0.061 (0.020--0.175)     84.951
  -------------------------------------------------------------------------------------

![All-grade AEs in the ten included studies (**A**) fixed-effects model; (**B**) random-effects model.](oncotarget-08-71117-g004){#F4}

The grade ≥ 3 toxicities were predominantly hematologic. Neutropenia/febrile neutropenia (17.5%, 95% CI 0.096--0.296, *I*^2^ = 84.806%, random-effects model), anemia (9.4%, 95% CI 0.035--0.228, *I*^2^ = 87.575%, random-effects model), fatigue (7.7%, 95% CI 0.049--0.118, *I*^2^ = 4.430%, fixed-effects model), sepsis (7.4%, 95% CI 0.038--0.142, *I*^2^ = 42.331%, fixed-effects model), and thrombocytopenia (6.1%, 95% CI 0.020--0.175, *I*^2^ = 84.951%, random-effects model) were the most frequent high-grade treatment-related adverse events (Table [2](#T2){ref-type="table"}, Figure [5](#F5){ref-type="fig"}).

![Grade 3 or more AEs in the ten included studies (**A**) fixed-effects model; (**B**) random-effects model..](oncotarget-08-71117-g005){#F5}

We further calculated the OR of all-grade adverse events between the dose-dense chemotherapy and classic chemotherapy groups. No statistical heterogeneity was observed in each adverse event except for thrombocytopenia, which was analyzed with a random-effects model. The results showed that compared with the classic MVAC group, dd-MVAC was associated with decreased risks of anemia (OR 0.457, 95% CI 0.249--0.840, *p =* 0.012, I^2^ = 0.000, fixed-effects model), febrile neutropenia (OR 0.398 95% CI 0.233--0.681, *p =* 0.001, I^2^ = 29.370%, fixed-effects model), and neutropenia (OR 0.373, 95% CI 0.201--0.691, *p =* 0.002, I^2^ = 0.000, fixed-effects model). Increased risks of kidney injury (OR 1.025, 95% CI 0.528--1.987, *p =* 0.943, I^2^ = 0.000, fixed-effects model) and neuropathy (OR 2.747, 95% CI 0.323--23.369, *p =* 0.355, I^2^=0.000, fixed-effects model) (Table [3](#T3){ref-type="table"}, Figure [6](#F6){ref-type="fig"}) were found for dd-MVAC, but there were no significant differences.

###### All-grade adverse events of dd-MVAC versus MVAC

  All-grade adverse events   Odds Ratio with 95% CI   Model          I^2^
  -------------------------- ------------------------ -------------- --------
  Anemia                     0.457 (0.249--0.840)     Fixed model    0.000
  Febrile neutropenia        0.398 (0.233--0.681)     Fixed model    29.370
  Kidney injury              1.025 (0.528--1.987)     Fixed model    0.000
  Neuropathy                 2.747 (0.323--23.369)    Fixed model    0.000
  Neutropenia                0.373 (0.201--0.691)     Fixed model    0.000
  Thrombocytopenia           0.888 (0.307--2.562)     Random model   76.634

![The odds ratios of adverse events (AEs) in the controlled trials comparing dd-MVAC and classic MVAC\
(**A**) fixed-effects model; (**B**) random-effects model.](oncotarget-08-71117-g006){#F6}

Risk of bias and quality assessment {#s2_5}
-----------------------------------

The risk of bias and quality assessments of the included studies are outlined in Figure [7A, 7B](#F7){ref-type="fig"}. The Jadad score of two controlled trials \[[@R7], [@R16]\] were 3 and one \[[@R9]\] got a score of 2. Overall, the quality of the included studies was satisfactory.

![Risk of bias and quality assessment\
(**A**) Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies; (**B**) Risk of bias summary: review authors' judgments about each risk of bias item for each included study.](oncotarget-08-71117-g007){#F7}

DISCUSSION {#s3}
==========

To the best of our knowledge, this is the first meta-analysis that assesses the tolerability and activity of dose-dense chemotherapy in patients with urothelial carcinoma. Dose-dense MVAC led to a significant increase in long-term survival and a decrease in all-grade adverse events. The pCR rate in the dose-dense group had a trend of increase compared with the classic chemotherapy group, although the difference was not statistically significant.

The degree of pathologic response is correlated with survival after UC surgery \[[@R18]\]. A meta-analysis demonstrated that patients with UC who achieved pCR after neoadjuvant chemotherapy had better OS than do patients without pCR. In breast cancer settings, the relationship between pCR and OS has been obscure, sometimes significantly associated \[[@R19], [@R20]\], but sometimes not \[[@R21], [@R22]\]. In our study, we assumed that the pCR rate and OS tended to increase in the dose-dense group, and no statistical difference might largely rely on the limited sample size.

The improved overall survival represented the advantage of long-term survival in dd-MVAC group, which was presumed to arise from the elimination of micrometastatic disease, instead of from improved local disease control \[[@R13]\]. In addition, better median progression-free survival was suggested by one study \[[@R16]\] with dd-MVAC (9.5 months) vs. classic MVAC (8.1 months) (HR = 0.73, 95% CI 0.56--0.95, *P =* 0.017).

Concomitantly, the toxicity data demonstrated that dd-MVAC was associated with a better tolerability than classic MVAC. The fewer adverse events were most probably due to bone marrow support with the routine addition of G-CSF \[[@R7], [@R16]\]. Toxicities may cause a delay in cystectomy or even deaths. All-grade AEs such as fatigue and thrombocytopenia were the most common, and it is suggested that surgeons still need to pay particular attention to grade ≥ 3 hematologic toxicities including neutrophil, erythrocyte and platelet toxicities.

The introduction of dose-dense combination chemotherapy provides advantages over standard chemotherapy. First, dose-dense chemotherapy has the potential to increase response rates as well as reduce the risk of progression and death \[[@R23], [@R24]\]. Second, a large proportion of patients achieved the planned number of cycles without serious life-threatening toxicity with the administration of G-CSF.

What's more, it is important to identify the optimal cycle of dd-MVAC. The number of cycles was variable in the included publications, but most studies adopted 3--5 cycles which displayed less toxicity and fewer dose delays.

There are several limitations in our study. First, because this dose-dense chemotherapy regimen is brought forward only recently which is rather new, there are few clinical trials about it. Second, the heterogeneity in our analysis could arise from the heterogeneous study population with pre-treated disease and the small sample size. Nevertheless, we used the random-effects model to reduce heterogeneity and also performed risk of bias and quality assessments and the Jadad score analyses to assess the quality of the included studies which turned out to be satisfactory.

Our systematic analyses of prospective and retrospective experiences with dd-MVAC suggested similar efficacy combined with better tolerability. We consider that the use of dose-dense chemotherapy regimen could be a trend in future treatment of patients with urothelial carcinoma. Further randomized trials comparing the two regimens are needed.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

We carried out a systematic literature search up to Nov 21, 2016 in PubMed, Medline, Embase, Web of Science and Cochrane Collaboration's Central register of controlled trials (CENTRAL), using the following search keywords: (dose dense OR dose-dense OR high-dose intensity OR accelerated OR dose-intensified OR dose-intensive) and (urothelial OR bladder) and (cancer OR carcinoma). There was no limit on the language of publications. We also carried out further searches for relevant unpublished trials in the clinical trial registry (<http://www.clinicaltrials.gov>).

Study selection criteria {#s4_2}
------------------------

The inclusion criteria for the current analysis were that studies (i) included patients diagnosed with urothelial cancer; (ii) evaluated dose-dense chemotherapy; (iii) reported survival outcomes of patients (pCR or OS or PFS or ORR); and (iiii) evaluated the toxicities.

Studies were excluded if (i) they were review articles, letters, comments, or case reports; (ii) they evaluated radiotherapy, or high-dose rather than dose-dense chemotherapy; (iii) the sample size was less than 20 patients. The study selection process was performed according to PRISMA flow diagrams. Two reviewers selected studies independently. Any disagreements were resolved through discussion with another author.

Data extraction {#s4_3}
---------------

We extracted the first author, year of publication, tumor type, study phase, sample size, chemotherapy regimens, the number of cycles of chemotherapy, patient characteristics (number of patients, sex, median age, and tumor stage). The number of patients achieving pCR and ORR, HRs for OS, and the number of chemotherapy-induced adverse events were also extracted from the papers.

Statistical analysis {#s4_4}
--------------------

The primary clinical endpoint used for the study was pCR, defined as the absence of histological evidence of invasive tumor cells (pT0N0M0 stage) \[[@R25]\]. The secondary clinical endpoints included (i) ORR, which was the summation of partial and complete response rates \[[@R26]\], (ii) OS, defined as the time from diagnosis of primary tumor to death, which can be from any cause \[[@R27]\], or the time to last contact; (iii) adverse events, which were graded according to the National Cancer Institute (Washington DC, USA) Common Toxicity Criteria.

For dichotomous outcomes, we calculated the odds ratio (OR) and 95% confidence intervals (CIs). For time-to-event data, we pooled the HR to compare the risk of death between the treatment group and the control group, using the generic inverse variance facility of RevMan \[[@R28]\]. A 2-tailed *p* value of less than 0.05 was considered as statistically significant. Statistical heterogeneity was defined as I^2^ \> 50% and *P* ≤ 0.1. If the heterogeneity existed, we used the random-effects model. All analyses were done with Comprehensive Meta-Analysis (CMA) program 2 (Biostat, Englewood, NJ) and Review manager 5.3 (Copenhagen, Sweden).

Risk of bias and quality assessment {#s4_5}
-----------------------------------

The assessment of risk of bias and the quality of the included studies was measured using Review Manager 5.3 (Copenhagen, Sweden). We applied the assessment tool QUADAS-2, which consisted of four key domains: patient selection, index test, reference standard and flow and timing. Risk of bias was rated as high/low/unclear. Two authors independently applied the risk of bias tool and differences were resolved by discussion with a third author.

We also utilized the Jadad scale to assess the qualities of the randomized controlled trials included in our study \[[@R29]\]. A score lower than 2 indicated that the clinical trial was of low quality while a score more than 3 indicated a high-quality design \[[@R30]\]. Two authors independently calculated the scores and differences were resolved by discussion with a third author.
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